BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pineton de Chambrun G, Tassy B, Kollen L, Dufour G, Valats J, Bismuth M, Funakoshi N, Panaro F, Blanc P. Refractory ulcerative proctitis: How to treat it? Best Practice & Research Clinical Gastroenterology 2018;32-33:49-57. [DOI: 10.1016/j.bpg.2018.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Zeng F, Li X, Deng X, Yao L, Lian G. An image classification model based on transfer learning for ulcerative proctitis. Multimedia Systems 2021;27:627-36. [DOI: 10.1007/s00530-020-00722-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 de Chambrun GP, Danese S, Peyrin-biroulet L. Time to include patients with ulcerative proctitis in clinical trials. The Lancet Gastroenterology & Hepatology 2019;4:900-2. [DOI: 10.1016/s2468-1253(19)30341-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-biroulet L, Nachury M, Boschetti G, Flourié B, Danion P, Savoye G, brazier F, Loreau J, Beaugerie L, Sokol H, Nion-larmurier I, Bourrier A, Landman C, Lefèvre J, Chafai N, Bouta N, Funakoshi N. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clinical Gastroenterology and Hepatology 2020;18:620-627.e1. [DOI: 10.1016/j.cgh.2019.05.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Shahrokh S, Qobadighadikolaei R, Abbasinazari M, Haghazali M, Asadzadeh Aghdaei H, Abdi S, Balaii H, Khanzadeh-Moghaddam N, Zali MR. Efficacy and Safety of Melatonin as an Adjunctive Therapy on Clinical, Biochemical, and Quality of Life in Patients with Ulcerative Colitis. Iran J Pharm Res 2021;20:197-205. [PMID: 34567156 DOI: 10.22037/ijpr.2020.113822.14508] [Reference Citation Analysis]
5 Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis 2021:jjab218. [PMID: 34850857 DOI: 10.1093/ecco-jcc/jjab218] [Reference Citation Analysis]
6 Chen YH, Xiang Y. Efficacy of resveratrol for the treatment in patients with ulcerative colitis: Study Protocol. Medicine (Baltimore) 2019;98:e17938. [PMID: 31725648 DOI: 10.1097/MD.0000000000017938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Stellingwerf ME, Bemelman W, Löwenberg M, Ponsioen CY, D'haens GR, Dieren S, Buskens CJ; the Parelsnoer Institute, the Dutch Initiative on Crohn, Colitis*a. A nationwide database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy? Colorectal Dis 2021;23:64-73. [DOI: 10.1111/codi.15184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Li Y, Yang X, Yuan J, Lin R, Tian Y, Li Y, Zhang Y, Wang X, Xie Y, Wang S, Zheng X. Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway. Front Pharmacol 2022;13:819826. [DOI: 10.3389/fphar.2022.819826] [Reference Citation Analysis]
9 Gao W, Wang C, Yu L, Sheng T, Wu Z, Wang X, Zhang D, Lin Y, Gong Y. Chlorogenic Acid Attenuates Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice through MAPK/ERK/JNK Pathway. Biomed Res Int 2019;2019:6769789. [PMID: 31139644 DOI: 10.1155/2019/6769789] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
10 Gu D, Nan Q, Miao Y, Yang H, Li M, Ye Y, Miao J. KT2 alleviates ulcerative colitis by reducing Th17 cell differentiation through the miR-302c-5p/STAT3 axis. Eur J Cell Biol 2022;101:151223. [PMID: 35405463 DOI: 10.1016/j.ejcb.2022.151223] [Reference Citation Analysis]
11 Niu W, Yang F, Fu Z, Dong Y, Zhang Z, Ju J. The role of enteric dysbacteriosis and modulation of gut microbiota in the treatment of inflammatory bowel disease. Microb Pathog 2021;:105381. [PMID: 34974123 DOI: 10.1016/j.micpath.2021.105381] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Pang L, Wang T, Liao Q, Cheng Y, Wang D, Li J, Fu C, Zhang C, Zhang J. Protective role of ergothioneine isolated from Pleurotus ostreatus against dextran sulfate sodium-induced ulcerative colitis in rat model. J Food Sci 2021. [PMID: 34873706 DOI: 10.1111/1750-3841.15982] [Reference Citation Analysis]
13 Zhang L, Cao N, Wang Y, Wang Y, Wu C, Cheng X, Wang C. Improvement of Oxazolone-Induced Ulcerative Colitis in Rats Using Andrographolide. Molecules 2019;25:E76. [PMID: 31878303 DOI: 10.3390/molecules25010076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut 2021;70:1203-9. [PMID: 33789968 DOI: 10.1136/gutjnl-2021-324108] [Reference Citation Analysis]
15 Dubois E, Moens A, Geelen R, Sabino J, Ferrante M, Vermeire S. Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. United European Gastroenterol J 2020;8:933-41. [PMID: 32631177 DOI: 10.1177/2050640620941345] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]